Exploratory study on the safety and efficacy of oral finerenone for renal function impairment after renal surgery

未提供0 个研究点目标入组 10 人开始时间: 待定

适应症

试验速览

暂无简介。

•(1) Patients who have undergone kidney surgery
•(2) Patients with diabetes mellitus who have an HbA1c >= 6.5% or are being treated with antidiabetic medication within 1 year prior to obtaining consent.
•(3) Patients with Chronic Kidney Disease (CKD).
•(4) Age: 18 years or older and less than 85 years at the time of obtaining consent.
•(5) Sex: Any.
•(6) Patients who have given written informed consent of their own free will after receiving a full explanation regarding participation in this study and fully understanding the contents.
•(7) Patients who are able to visit the outpatient clinic according to the study schedule

•(1) Patients requiring treatment with anticancer drugs or similar agents.
•(2) Patients with active renal or systemic inflammation.
•(3) Patients with an eGFR < 25 mL/min/1.73 m
•(4) Patients with a history of allergy to finerenone.
•(5) Patients currently receiving medications containing itraconazole, posaconazole, voriconazole, or ritonavir; medications containing atazanavir, darunavir, fosamprenavir, or cobicistat; clarithromycin; or ensitrelvir.
•(6) Patients with a serum potassium level > 4.8 mEq/L at the time of enrollment.
•(7) Patients with severe hepatic impairment (Child-Pugh Class C).
•(8) Patients with Addison's disease.
•(9) Patients who are pregnant or possibly pregnant.
•(10) Patients who are breastfeeding.
•(11) Any other patients deemed ineligible for participation in this study by the Principal Investigator or Co-Investigator

发起方

未提供